Next-Generation
Platelet-based Therapeutics

PlaBiTe is developing a new class of biologic medicines based on platelet secretome for regenerative medicine. Our lead program is focused on chronic wounds.

therapeutic development pipeline

Pletelet secretome platform

Harnessing the natural regenerative potencial of human pletelets

Biologic Therapeutics

Cell-free, human-derived therapeutics with defined mechanisms of action.

Rigorous development

Following regulatory standards for safety, quality and efficacy at every step

Patient impact

Addressing high unmet need in chronic wounds and other regenerative indications

Program

PBT-P

Lead candidate
First indication: chronic wounds

Proof of concept

Mechanism exploration and proof of concept in laboratory scale

Preclinical research

Characterization of the platelet secretome and in vitro efficacy studies

CMC and GMP-like manufacturing

Scale-up and pharmaceutical development

GLP preclinical program

Final study scope defined after AEMPS interaction. Scientific advice or pre-CTA discussion to align the preclinical strategy

Phase I/II

First-in-human safety and preliminary efficacy in target patients

Committed to quality and regulatory excellence

We are building a robust quality system to ensure the consistency, safety and traceability of our GMP-like batches, supporting the requirements of regulated preclinical studies and future clinical development.